藥 物 設 計 及 化 學 生 物 核 心 實 驗 室
Welcome to Prof. Ming-Hon Hou's Laboratory at NCHU
Ming-Hon Hou (教授資訊)
Lab 712 Members (實驗室成員)
Research Topics (研究方向)
Overview
In order to solve the health problems that human beings are facing today, our research focuses on the development of novel drugs against several important infectious diseases, genetic diseases, and cancers.
Our major research projects include:
-
Development of antiviral drugs targeting the nucleocapsid protein against emerging viruses.
-
Development of anticancer drugs targeting DNA or RNA.
-
Development of diagnostic tools for genetic diseases associated with unusual DNA structures.
April 2026- Our research paper, "Structural basis for asymmetric bis-intercalator targeting of DNA triplex junctions enabling dual inhibition of topoisomerase I and oncogene transcription" has been accepted in Nucleic Acids Research. Congratulations to Prof. Hou and the team on this achievement!
March 2025- Our research paper on 'Structural and Functional Insights into Targeting GCCG Sites in the EGFR Promoter by Two DNA Intercalators to Inhibit Breast Cancer Metastasis' has been published in Journal of Medicinal Chemistry. Congratulations Prof. Hou and our team!
October 2024- We are delighted to share that our research paper, "Antiviral Drug Development by Targeting the RNA Binding Site, Oligomerization, and Nuclear Export of Influenza Nucleoprotein," has been published in International Journal of Biological Macromolecules. Congratulations to Prof. Hou and our team!
July 2024- Our research paper on 'Targeting DNA junction sites by bis-intercalators induces topological changes with potent
antitumor effects' has been published in Nucleic Acids Research. Congratulations Prof. Hou and the team!
中興大學領先研發雙嵌入劑癌症新藥 (Doxactino) 為三陰性乳癌帶來新曙光
三陰性乳癌因缺乏有效標靶藥物，病程進展快速、易轉移且預後不良，為難治的乳癌亞型之一。傳統化療藥物小紅莓應具有心臟毒性，且有使用劑量限制，在治療上具有瓶頸。侯明宏教授領導的研究團隊採用低劑量 Actinomycin D 作為 DNA 導引劑，促進 Doxorubicin 精準嵌入與作用。雙藥協同作用，可有效抑制 EGFR 表現，抑制腫瘤細胞生長與轉移，研究成果已於 2025 年 3 月發表於國際權威期刊《醫學化學期刊》，並獲選為當期封面文章，突顯其在癌症標靶治療領域的重要創見。該療法命名為「Doxactino」，象徵其結合 Doxorubicin 與 Actinomycin D 的協同作用與臨床應用潛力。
興大人物誌|十年磨一劍 興大侯明宏教授投入抗冠狀病毒藥物開發
新冠肺炎疫情再度升溫，確診人員屢破新高。中興大學5月份發行《興大人物誌》影片，紀錄基因體暨生物資訊學研究所教授侯明宏從2003年SARS爆發至今，投入冠狀病毒研究的歷程。十多年來他孤軍奮戰，直至2020年3月，所提出以核殼蛋白作為冠狀病毒藥物開發標的之研究，終登《藥物化學》國際期刊封面，至今下載次數破萬，為全球抗冠狀病毒藥物開展新方向。
2022學術能量專區—生命科學領域教師專訪(中興大學基因體暨生物資訊學研究所 侯明宏教授主講)
｜講題｜
2022學術能量專區—生命科學領域教師專訪
｜講者｜中興大學基因體暨生物資訊學研究所 侯明宏教授
We welcome you to join "Nucleic Acids: Prospect and Therapeutic Applications"
at
National Chung Hsing University
on
July, 07, 2023
We are happy to share a new website for our upcoming event this year in 2022......
For more info contact:
Find us:
